Literature DB >> 9519438

Radionuclide development at BNL for nuclear medicine therapy.

L F Mausner1, K L Kolsky, V Joshi, S C Srivastava.   

Abstract

Radionuclides with medium energy beta emission and a several day half-life have often been viewed as attractive candidates for radioimmunotherapy. Among the most promising in this category are 47Sc, 67Cu, 153Sm, 188Re, and 199Au. The production of 67Cu, 153Sm, 199Au at BNL is summarized and the development of the latest candidate for this application, 47Sc, is described in detail. We also summarize the development of another important therapeutic radionuclide, 117mSn for bone pain palliation.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9519438     DOI： 10.1016/s0969-8043(97)00040-7

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN： 0969-8043            Impact factor:   1.513


  9 in total

1.  ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine.

Authors:  Ferid Haddad; Ludovic Ferrer; Arnaud Guertin; Thomas Carlier; Nathalie Michel; Jacques Barbet; Jean-François Chatal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

2.  Stability of 47Sc-complexes with acyclic polyamino-polycarboxylate ligands.

Authors:  Magdalena Połosak; Agata Piotrowska; Seweryn Krajewski; Aleksander Bilewicz
Journal:  J Radioanal Nucl Chem       Date:  2012-09-13       Impact factor: 1.371

3.  Feasibility of isotope harvesting at a projectile fragmentation facility: ⁶⁷Cu.

Authors:  Tara Mastren; Aranh Pen; Graham F Peaslee; Nick Wozniak; Shaun Loveless; Scott Essenmacher; Lee G Sobotka; David J Morrissey; Suzanne E Lapi
Journal:  Sci Rep       Date:  2014-10-21       Impact factor: 4.379

4.  47Sc production development by cyclotron irradiation of 48Ca.

Authors:  R Misiak; R Walczak; B Wąs; M Bartyzel; J W Mietelski; A Bilewicz
Journal:  J Radioanal Nucl Chem       Date:  2017-06-13       Impact factor: 1.371

5.  47Sc as useful β--emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes.

Authors:  Katharina A Domnanich; Cristina Müller; Martina Benešová; Rugard Dressler; Stephanie Haller; Ulli Köster; Bernard Ponsard; Roger Schibli; Andreas Türler; Nicholas P van der Meulen
Journal:  EJNMMI Radiopharm Chem       Date:  2017-06-02

6.  Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT.

Authors:  Guiyang Hao; Tara Mastren; William Silvers; Gedaa Hassan; Orhan K Öz; Xiankai Sun
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

7.  Cyclotron production of (43)Sc for PET imaging.

Authors:  Rafał Walczak; Seweryn Krajewski; Katarzyna Szkliniarz; Mateusz Sitarz; Kamel Abbas; Jarosław Choiński; Andrzej Jakubowski; Jerzy Jastrzębski; Agnieszka Majkowska; Federica Simonelli; Anna Stolarz; Agnieszka Trzcińska; Wiktor Zipper; Aleksander Bilewicz
Journal:  EJNMMI Phys       Date:  2015-12-04

Review 8.  New Radionuclides and Technological Advances in SPECT and PET Scanners.

Authors:  Nicholas P van der Meulen; Klaus Strobel; Thiago Viana Miranda Lima
Journal:  Cancers (Basel)       Date:  2021-12-08       Impact factor: 6.639

9.  Production scheme for diagnostic-therapeutic radioisotopes by accelerator neutrons.

Authors:  Yasuki Nagai
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2021       Impact factor: 3.493
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.